Literature DB >> 9069485

Spontaneous neurological improvement in anti-Hu associated encephalomyelitis.

T Byrne1, W P Mason, J B Posner, J Dalmau.   

Abstract

Symptoms of anti-Hu associated paraneoplastic encephalomyelitis (PEM) and sensory neuropathy (PSN) are usually severe and irreversible. Two patients are reported whose symptoms improved spontaneously, and in one of them they resolved after resection of an inflammatory lesion of the lung. Spontaneous neurological improvement, although rare, should be considered in the evaluation of therapies for PEM/PSN.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9069485      PMCID： PMC1064159          DOI： 10.1136/jnnp.62.3.276

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  14 in total

1.  Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.

Authors:  J Dalmau; F Graus; M K Rosenblum; J B Posner
Journal:  Medicine (Baltimore)       Date:  1992-03       Impact factor: 1.889

2.  Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies.

Authors:  M Uchuya; F Graus; F Vega; R Reñé; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-04       Impact factor: 10.154

3.  Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin.

Authors:  C E Counsell; M McLeod; R Grant
Journal:  Neurology       Date:  1994-06       Impact factor: 9.910

4.  Spontaneous regression of small cell carcinoma of lung associated with severe neuropathy.

Authors:  W Zaheer; M L Friedland; E B Cooper; A DoRosario; R M Burd; J Gagliardi; G Torstenson
Journal:  Cancer Invest       Date:  1993       Impact factor: 2.176

5.  Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer.

Authors:  N E Anderson; M K Rosenblum; F Graus; R G Wiley; J B Posner
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

6.  Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis.

Authors:  J Dalmau; H M Furneaux; R J Gralla; M G Kris; J B Posner
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

7.  Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption.

Authors:  L M Cher; F H Hochberg; J Teruya; M Nitschke; R F Valenzuela; J D Schmahmann; M Herbert; H D Rosas; C Stowell
Journal:  Cancer       Date:  1995-04-01       Impact factor: 6.860

8.  Indolent anti-Hu-associated paraneoplastic sensory neuropathy.

Authors:  F Graus; I Bonaventura; M Uchuya; J Valls-Solé; R Reñé; J M Leger; E Tolosa; J Y Delattre
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

9.  Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy.

Authors:  J Dalmau; H M Furneaux; M K Rosenblum; F Graus; J B Posner
Journal:  Neurology       Date:  1991-11       Impact factor: 9.910

10.  Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies.

Authors:  F Graus; F Vega; J Y Delattre; I Bonaventura; R Reñé; D Arbaiza; E Tolosa
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910
View more
  9 in total

Review 1.  Relative paradigms between autoantibodies in lupus and autoantibodies in cancer.

Authors:  E M Tan; F-D Shi
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

2.  A myxoid chondrosarcoma associated with an anti-Hu-positive paraneoplastic encephalomyelitis.

Authors:  Michael Hoosien; James Vredenburgh; Julio Lanfranco; Roberto Ochoa; Philip Robinson; Robert Martinez; Carlos Singer; Orlando Silva
Journal:  J Neurooncol       Date:  2010-05-05       Impact factor: 4.130

3.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.

Authors:  F Keime-Guibert; F Graus; A Fleury; R René; J Honnorat; P Broet; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

Review 4.  Diagnosis and current treatment of neurological paraneoplastic syndromes.

Authors:  María José Molina-Garrido; Carmen Guillén-Ponce; Salvador Martínez; María Guirado-Risueño
Journal:  Clin Transl Oncol       Date:  2006-11       Impact factor: 3.405

5.  Paraneoplastic antineuronal antibodies in patients with systemic autoimmune diseases.

Authors:  B Benyahia; Z Amoura; A Rousseau; C Le Clanche; A Carpentier; J C Piette; J Y Delattre
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

6.  Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction.

Authors:  Francisco Coret; Isabel Bosca; Loren Fratalia; Jaume Perez-Griera; Ana Pascual; Bonaventura Casanova
Journal:  J Neurooncol       Date:  2009-01-13       Impact factor: 4.130

7.  Current Therapies for Paraneoplastic Neurologic Syndromes.

Authors:  Myrna R. Rosenfeld; Josep Dalmau
Journal:  Curr Treat Options Neurol       Date:  2003-01       Impact factor: 3.598

Review 8.  Are onconeural antibodies a clinical phenomenology in paraneoplastic limbic encephalitis?

Authors:  Hongliang Zhang; Chunkui Zhou; Limin Wu; Fengming Ni; Jie Zhu; Tao Jin
Journal:  Mediators Inflamm       Date:  2013-07-25       Impact factor: 4.711

Review 9.  Cell-mediated immune responses in paraneoplastic neurological syndromes.

Authors:  Mikolaj Piotr Zaborowski; Slawomir Michalak
Journal:  Clin Dev Immunol       Date:  2013-12-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.